Cost-effectiveness Analysis of Domestic and Imported Vancomycin in the Treatment of Intracranial Infection Induced by MRSA by Using Decision Tree Model
- VernacularTitle:运用决策树模型对国产和进口万古霉素治疗耐甲氧西林金黄色葡萄球菌颅内感染进行成本-效果分析
- Author:
Chun HUANG
1
;
Fanlu MO
1
;
Xingnan QIN
1
;
Hongliang ZHANG
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Guangxi Medical Univer sity，Nanning 530021，China
- Publication Type:Journal Article
- Keywords:
Decision tree model;
Laikexin;
Vancocin;
Intracranial infection induced by MRSA;
Cost-effectiveness ratio
- From:
China Pharmacy
2019;30(9):1256-1259
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE： To analyze effectiveness and economy of domestic vancomycin hydrochloride for injection （trade name： Laikexin） vs. imported vancomycin hydrochloride for injection （trade name： Vancocin） in treatment of intracranial infection induced by MRSA， and to provide decision-making reference for the selection of clinical drugs. METHODS： Clinical data of patients with suspected MRSA intracranial infections receiving Laikexin or Vancocin were collected by retrospective study method from neurosurgery department of our hospital during Jan. 2016 to Jun. 2017， including 115 cases of Laikexin and 42 cases of Vancocin. Using response rate （including clinical cure and clinical improvement） as indexes， cost-effectiveness analysis was performed for Laikexin and Vancocin in the treatment of intracranial infection induced by MRSA by using decision tree model. Sensitivity analysis was conducted for 10％ decrease of cost and response rate. RESULTS： Response rate and excepted cost of Laikexin were 85.21％ and 13 125.96 yuan， cost-effectiveness ratio （CER） was 15 404.25. Response rate and excepted cost of Vancocin were 78.57％ and 15 619.17 yuan， CER was 19 879.31. There was no statistical significance in response rate between Laikexin and Vancocin （P＜0.05）. There was no difference between sensitivity analysis and cost-effectiveness analysis. CONCLUSIONS： The efficacy of Laikexin and Vancocin in the treatment of MRSA intracranial infection is similar， but the CER of Laikexin is lower than that of Wenkexin.
